ArticleThe World Allergy Organization journal2025
Increased LOXL2 facilitates tissue remodeling in eosinophilic chronic rhinosinusitis with nasal polyps.
Article in The World Allergy Organization journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ATP/P2X7 signaling as a potential predictive biomarker for early recurrence of nasal polyps: Correlation with inflammasome activation and epithelial barrier dysfunction.The World Allergy Organization journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Eosinophilic chronic rhinosinusitis with nasal polyps (eCRSwNP) involves extensive tissue remodeling, but its underlying mechanisms remain unclear. This study aimed to identify key regulatory proteins contributing to this process. Methods: Proteomic analysis was conducted on nasal tissues from 8 eCRSwNP patients, 8 non-eosinophilic CRSwNP (neCRSwNP) patients, and 8 healthy controls. Differentially expressed proteins (DEPs) were selected based on the top 50 overlapping DEPs from both comparison groups. Selected candidates were validated using Western blotting, immunofluorescence, and qRT-PCR in an independent cohort. Correlations with eosinophil infiltration and remodeling markers were assessed. Human nasal epithelial cells (HNECs) were used to explore functional mechanisms in vitro. Result: Proteomic profiling revealed a distinct protein expression signature in the eCRSwNP group compared to both neCRSwNP and control groups. By intersecting the top 50 DEPs from both comparisons, 4 candidate proteins were identified, among which lysyl oxidase-like protein 2 (LOXL2) exhibited the most prominent upregulation. Validation in an independent cohort confirmed significantly elevated LOXL2 expression in eCRSwNP, predominantly localized to the nasal epithelial region (P < 0.001). LOXL2 mRNA levels were strongly correlated with eosinophil infiltration in nasal tissues (r = 0.349, P = 0.006), and ROC curve analysis supported its high diagnostic utility for eCRSwNP (AUC = 0.746, P = 0.001). Furthermore, the expression of EMT markers including vimentin, α-smooth muscle actin (α-SMA), and N-cadherin was markedly increased in eCRSwNP tissues (all P < 0.01) and positively associated with LOXL2 expression (all P < 0.05). In vitro, stimulation of HNECs with recombinant LOXL2 induced TGF-β1 and EMT marker expression, while co-treatment with the TGF-β1/Smad signaling inhibitor LY364947 significantly attenuated these effects and inhibited Smad2/3 phosphorylation. Conclusion: Our findings revealed a disease-specific protein profile in eCRSwNP, characterized by selective upregulation of LOXL2 in the nasal epithelium and strong association with eosinophilic inflammation. Functional studies suggest that LOXL2 promotes EMT and may drive tissue remodeling in eCRSwNP via the TGF-β1/Smad signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.